Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

Relyvrio Being Pulled From The Market For ALS Was A Setback, But A New Possibility Emerges AMX0035 Has Two Shots On Goal To Possibly Boost Shareholder Value Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) suffered a major setback this year when it voluntarily delisted its Amyotrophic lateral sclerosis [ALS] drug Relyvrio on April 4th of 2024. This was a huge blow to the company, definitely, but that doesn't mean that it doesn't have some opportunities to redeem itself in the coming years. What I'm talking about ...